These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8316825)

  • 1. Teaching the immune system to fight cancer.
    Boon T
    Sci Am; 1993 Mar; 268(3):82-9. PubMed ID: 8316825
    [No Abstract]   [Full Text] [Related]  

  • 2. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
    Marincola FM; Jaffee EM; Hicklin DJ; Ferrone S
    Adv Immunol; 2000; 74():181-273. PubMed ID: 10605607
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes.
    De Plaen E; Lurquin C; Lethé B; van der Bruggen P; Brichard V; Renauld JC; Coulie P; Van Pel A; Boon T
    Methods; 1997 Jun; 12(2):125-42. PubMed ID: 9184377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: natural versus synthetic peptides.
    Protti MP; Bellone M
    Immunol Today; 1998 Feb; 19(2):98. PubMed ID: 9509766
    [No Abstract]   [Full Text] [Related]  

  • 5. Symposium-in-writing. Introduction.
    Whiteside TL
    Clin Immunol Immunopathol; 1994 Jun; 71(3):247. PubMed ID: 7911076
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
    Ando M; Nakauchi H
    Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RNA-loaded dendritic cells].
    Hinoda Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():613-8. PubMed ID: 15861719
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
    Boon T
    Int J Cancer; 1993 May; 54(2):177-80. PubMed ID: 8486420
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer.
    Araki K; Noguchi Y; Hirouchi T; Yoshikawa E; Kataoka S; Silverni L; Miyazawa H; Kuzuhara H; Suzuki C; Shimada Y; Hamasato S; Maeda N; Shimamura Y; Ogawa Y; Ohtsuki Y; Fujimoto S
    Int J Oncol; 2000 Dec; 17(6):1107-18. PubMed ID: 11078795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 11. The structure and function of MHC molecules. Possible implications for the control of tumor growth by MHC-restricted T cells.
    Kourilsky P; Jaulin C; Ley V
    Semin Cancer Biol; 1991 Oct; 2(5):275-82. PubMed ID: 1773044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
    Vigneron N; Abi Habib J; Van den Eynde BJ
    Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining tumor antigens: mRNA, protein or cytotoxicity?
    Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
    Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of immune lysis of tumor cells by interferon.
    Ng AK; Imai K; Pellegrino MA; Vitiello A; Indiveri F; Wilson BS; Ferrone S
    Biomembranes; 1983; 11():313-39. PubMed ID: 6187384
    [No Abstract]   [Full Text] [Related]  

  • 16. [HLA-restricted cancer-specific killer T cells].
    Harada M; Itoh K
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():579-84. PubMed ID: 15861714
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
    Coulie PG
    Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological ignorance of silent antigens as an explanation of tumor evasion.
    Chen L
    Immunol Today; 1998 Jan; 19(1):27-30. PubMed ID: 9465485
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
    Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
    Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.